LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member] |
12 Months Ended |
|---|---|
|
Mar. 31, 2021
USD ($)
| |
| Agreement description | Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin |
| Issuance of license agreement | $ 5,000,000 |
| Royalty rate | 9.00% |
| Net sales | 20 years |